You are still hoping for herd immunity. It can't be achieved, not with these vaccines at least. They're too leaky. Even if you vaccinate 100% of the people you won't achieve herd immunity. Currently that is an impossible goal. Clinging to this hope is a mistake.
You need mucosal immunity, and that's a tough nut to crack. Unfortunately those working on vaccines with that aim were pushed out of the market, and therefore out of both funding and state sponsorship, by the availability of these - to be direct - crappy* vaccines.
It's one of those cases where a vaccine deemed "good enough", coupled with exclusively for-profit development, and with governments wanting their qhick fix now, are screwing us in the long term.
These vaccines have one "public interest" advantage and one only: they do seem to reduce hospital demand during covid peaks. But they won't end them and having seen the irresponsible behaviour of our rules that means they'll just let the "wave" get higher, more people infected, until the NPI are again deployed. So far we've seen that in the US with the official walkback for masking again. And informally, spontaneously, in the UK as people took up masking also. This is not a return to normal.
*Crappy because if they do reduce relative risk, that reduction doesn't seem great and they'll just be used as an excuse to let the absolute risk rise until the hospitals clog again. We'll see come Autumn, classes, the continued attempt to "reopen" as people shift indoors. End result is more people suffering bouts of supposedly "non-serious" covid which will leave them scarred. Something that reduces relative risk may, if used unwisely, actually elevate the absolute risk for everyone. That's what is happening with the vaccination campaign strategy.
Voltaire 18th century:
"the best is the enemy of the good"
Robert Alexander Watson-Watt in ww2:
"Always strive to give the military the third best because the best is impossible and second best is always too late."
(he was responsible for the UK having radar defense just in time for the Battle of Britain)
The Cult of the Imperfect:
https://www.psychologytoday.com/us/blog/am-i-right/201411/the-cult-the-imperfect
Not something fancy. Lean Manufacturing is based on it. Not aiming for the perfect solution but
a nurturing improvement process with good enough start conditions and settings.
Nothing wrong with the quick fixes we went through (the hammer & the dance lock-downs) and are now going through: max vaccination rates with the current generation vaccins.
Buying time meanwhile keeping the ship afloat.
Not every captain of the same qualities, not every crew and passengers of the same qualities... but that's life.
You can call it hope... I would call it direction without clear sight what lays beyond the horizon.
On those nasal vaccins.
They are in development and I am not aware of visible signs of obstruction. And yes... this kind of research does take time. Not a pizza in a 380 C furnace.
As it happened there was four days ago an article in Trouw (Dutch newspaper) on one of those nasal spreay vaccins that is being developed in NL by Intravacc.
Novel in this spray is that it uses bacterial membrane vesicles as package for the vaccin.
On bacterial vesicles in general:
https://www.nature.com/articles/s41579-018-0112-2
Abstract
Most bacteria release membrane vesicles (MVs) that contain specific cargo molecules and have diverse functions, including the transport of virulence factors, DNA transfer, interception of bacteriophages, antibiotics and eukaryotic host defence factors, cell detoxification and bacterial communication. MVs not only are abundant in nature but also show great promise for applications in biomedicine and nanotechnology. MVs were first discovered to originate from controlled blebbing of the outer membrane of Gram-negative bacteria and are therefore often called outer-membrane vesicles (OMVs). However, recent work has shown that Gram-positive bacteria can produce MVs, that different types of MVs besides OMVs exist and that, in addition to membrane blebbing, MVs can also be formed by endolysin-triggered cell lysis. In this Review, we provide an overview of the structures and compositions of the various vesicle types and discuss novel formation routes, which may lead to distinct vesicle types that serve particular functions.
From a Trouw article of April 2021 in more layman wording:
https://www.trouw.nl/wetenschap/neusspray-uit-bilthoven-mengt-zich-in-vaccinwedloop~b2e2ed7f/
A corona vaccine developed by Intravacc in Bilthoven has passed the first test phase well. The vaccine provides very good protection against the virus in laboratory animals. This means that the company can prepare for the next phase: testing for safety and efficacy in humans. It is expected to start at the end of this year.
Worldwide, twelve vaccines are now fully or partially authorized and more than a hundred are already in that clinical phase. Yet Dinja Oosterhoff, program director at Intravacc, is not afraid that her vaccine will come after a meal like mustard. The world is far from getting rid of the coronavirus and Oosterhoff is convinced that a second generation of vaccines is needed.
Intranasal vaccine
Intravacc's vaccine can then be distinctive, she says. It's an intranasal vaccine – it's given with a nasal spray. “That means the first line of defense is already in the nasal mucus,” she says. “In addition, such a vaccine better prevents the virus from being transmitted. Of all the vaccines that have now been or are being developed, only a few intranasal vaccines are in the clinical phase.”
That is not the only distinguishing feature of the Bilthoven vaccine. Like almost all other corona vaccines, this also focuses on the so-called spike protein with which the virus gains access to the cells. But where other vaccines use a fat globule or a weakened virus to carry the genetic code of this protein, Intravacc has resorted to bacteria. To the vesicles with which bacteria communicate with each other, to be precise. These bacterial vesicles are not only cheap to produce, they are also dead material that cannot multiply in the body of the vaccinated person.
Intravacc already had experience with the vesicles, but then as a vaccine against the bacteria itself. Now they also appear to be suitable as a means of transport in a corona vaccine. At least in lab animals. All but one mouse developed neutralizing antibodies to the virus. Vaccinated hamsters did not become ill after exposure (mice are not susceptible to this virus) and none of them suffered any lung damage.
Clinical phase difficult
That convinces us that the vaccine is effective, says Oosterhoff. “We are now moving full steam ahead towards the clinical trial.” She assumes that the vaccine also produces a cellular immune response in humans; something that has not been looked at in the hamsters because of their specific defenses.
That clinical phase is still going to be difficult. After all, this requires test subjects who have not yet been in contact with the virus or a vaccine. If it is up to Minister Hugo de Jonge, they will no longer be available in the Netherlands by the end of this year. But maybe things aren't going so fast here, Oosterhoff responds.
This is not so important for the first phase of clinical research. This mainly concerns the safety of the vaccine and the participants may already have antibodies against the virus. And for the future, the fact that it is a nasal vaccine also offers opportunities. After all, in the nose, the built-up defenses sink the fastest. Then the intranasal vaccine can show whether it generates a new immune response.
And the update a week ago: all still going well
https://www.trouw.nl/wetenschap/int...-dit-is-geen-mosterd-na-de-maaltijd~b5c0f4ca/
A year ago it seemed the question of whether vaccines would come, and when, now there are some very effective ones available. Intravacc, which is based in Bilthoven, announced last spring that it has developed a vaccine that is safe and effective in laboratory animals. Safety studies will follow in the near future, after which the vaccine can be tested on humans at the beginning of 2022. First on safety, then on efficacy and effectiveness. The vaccine, which has been dubbed Avacc 10, should be available by the end of 2022. How do people from Intravacc estimate their chances?
Jan Groen: “It is a unique vaccine. There are still 272 vaccines under development worldwide. Most are, or need to be, injected. Our vaccine will be administered by nasal spray. That route is followed by only seven other vaccines. And within that group we also use a special technique.
“Scientifically it makes sense to use a nasal spray. After all, the virus also often enters through the nose. Our vaccine therefore immediately attacks the virus. If you introduce a vaccine into the body via a muscle, the local defenses are much lower. And because you apply it in the nose, you also ensure the production of specific antibodies, immunoglobulin A, which form the first defense precisely in the mucous membranes.
“A nasal spray is easier to administer. You must be medically qualified to give a shot. That is why our vaccine would be suitable for use in countries with a less developed medical infrastructure. Also because it is much cheaper than, for example, the RNA vaccines and also does not have to be stored in freezers. And don't forget the Netherlands. One in three adults and half of children have a fear of needle sticks.
As small side step:
Interestingly the fear for needles is here mentioned.
Many more people have issues here than we think.
We are all so d****d social and political correct, that you cannot simply grap all cows at their horns.
When you play cards during lunch break at work and come with some fancy story why you don't want a vaccin... the first remark (at least in Amsterdam workers culture) that you get tossed to your head if you profiled too much as "the tough guy":
"ohhh... afraid for needles ?"
I don't want to derogate people afraid for needles, but making a taboo of it, is not gonna help adressing it.
And BTW the fainting of people with needle fear happens mostly after they got jabbed and relax again away from the build up tension and faint from the blood pressure drop. Such people should get their jab lying down on a bed or table.
And back on topic:
Perhaps the transport technique here developed by Intravacc is in the bigger picture more important than their vaccin.
But then another vaccin will make use of the gained knowledge to transport it to the nasal mucus.